$848.50 - $6,050.50

$848.50 - $6.00

Choose an Option...
  • 100 mg - $6,050.50
  • 50 mg - $4,277.50
  • 25 mg - $2,842.00
  • 5 mg - $848.50
  • Custom Amount (Quotes Only)
In stock
Only %1 left
  • US Customers - Order by Noon EDT on Monday to receive by June 16.
  • You may also be interested in:

    Product Description

    The polyclonal Armenian hamster IgG is purified from Armenian hamster serum. It is ideal for use as a non-reactive control IgG for Armenian hamster antibodies in most in vivo and in vitro applications.

    Specifications

    Isotype Armenian hamster IgG
    Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
    Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
    Formulation PBS, pH 7.0
    Contains no stabilizers or preservatives
    Endotoxin* ≤0.5EU/mg (≤0.0005EU/μg)
    Determined by LAL assay
    Aggregation* <5%
    Determined by DLS
    Purity ≥95%
    Determined by SDS-PAGE
    Sterility 0.2 µm filtration
    Production Purified from Armenian hamster serum
    Purification Protein G
    RRID AB_1107773
    Molecular Weight 150 kDa
    Murine Pathogen Tests* Ectromelia/Mousepox Virus: Negative
    Hantavirus: Negative
    K Virus: Negative
    Lactate Dehydrogenase-Elevating Virus: Negative
    Lymphocytic Choriomeningitis virus: Negative
    Mouse Adenovirus: Negative
    Mouse Cytomegalovirus: Negative
    Mouse Hepatitis Virus: Negative
    Mouse Minute Virus: Negative
    Mouse Norovirus: Negative
    Mouse Parvovirus: Negative
    Mouse Rotavirus: Negative
    Mycoplasma Pulmonis: Negative
    Pneumonia Virus of Mice: Negative
    Polyoma Virus: Negative
    Reovirus Screen: Negative
    Sendai Virus: Negative
    Theiler’s Murine Encephalomyelitis: Negative
    Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
    Need a Custom Formulation? See All Antibody Customization Options
    * Additional quality control measures for our InVivoPlus™ products include advanced binding validation, murine pathogen screening, protein aggregation screening, and ultra-low endotoxin levels. The superior quality of our InVivoPlus™ products will meet and exceed the strict demands and rigorous standards required for in vivo research. Learn more about the InVivoPlus™ difference here.

    Application References

    • Khmaladze, I., et al (2014). "Mannan induces ROS-regulated, IL-17A-dependent psoriasis arthritis-like disease in mice" Proc Natl Acad Sci U S A 111(35): E3669-3678.

      Psoriasis (Ps) and psoriasis arthritis (PsA) are poorly understood common diseases, induced by unknown environmental factors, affecting skin and articular joints. A single i.p. exposure to mannan from Saccharomyces cerevisiae induced an acute inflammation in inbred mouse strains resembling human Ps and PsA-like disease, whereas multiple injections induced a relapsing disease. Exacerbation of disease severity was observed in mice deficient for generation of reactive oxygen species (ROS). Interestingly, restoration of ROS production, specifically in macrophages, ameliorated both skin and joint disease. Neutralization of IL-17A, mainly produced by gammadelta T cells, completely blocked disease symptoms. Furthermore, mice depleted of granulocytes were resistant to disease development. In contrast, certain acute inflammatory mediators (C5, Fcgamma receptor III, mast cells, and histamine) and adaptive immune players (alphabeta T and B cells) were redundant in disease induction. Hence, we propose that mannan-induced activation of macrophages leads to TNF-alpha secretion and stimulation of local gammadelta T cells secreting IL-17A. The combined action of activated macrophages and IL-17A produced in situ drives neutrophil infiltration in the epidermis and dermis of the skin, leading to disease manifestations. Thus, our finding suggests a new mechanism triggered by exposure to exogenous microbial components, such as mannan, that can induce and exacerbate Ps and PsA.

    • Awe, O., et al (2015). "PU.1 Expression in T Follicular Helper Cells Limits CD40L-Dependent Germinal Center B Cell Development" J Immunol .

      PU.1 is an ETS family transcription factor that is important for the development of multiple hematopoietic cell lineages. Previous work demonstrated a critical role for PU.1 in promoting Th9 development and in limiting Th2 cytokine production. Whether PU.1 has functions in other Th lineages is not clear. In this study, we examined the effects of ectopic expression of PU.1 in CD4+ T cells and observed decreased expression of genes involved with the function of T follicular helper (Tfh) cells, including Il21 and Tnfsf5 (encoding CD40L). T cells from conditional mutant mice that lack expression of PU.1 in T cells (Sfpi1lck-/-) demonstrated increased production of CD40L and IL-21 in vitro. Following adjuvant-dependent or adjuvant-independent immunization, we observed that Sfpi1lck-/- mice had increased numbers of Tfh cells, increased germinal center B cells (GCB cells), and increased Ab production in vivo. This correlated with increased expression of IL-21 and CD40L in Tfh cells from Sfpi1lck-/- mice compared with control mice. Finally, although blockade of IL-21 did not affect GCB cells in Sfpi1lck-/- mice, anti-CD40L treatment of immunized Sfpi1lck-/- mice decreased GCB cell numbers and Ag-specific Ig concentrations. Together, these data indicate an inhibitory role for PU.1 in the function of Tfh cells, germinal centers, and Tfh-dependent humoral immunity.

    • Ballesteros-Tato, A., et al (2014). "Epitope-specific regulation of memory programming by differential duration of antigen presentation to influenza-specific CD8(+) T cells" Immunity 41(1): 127-140.

      Memory CD8(+) T cells are programmed during the primary response for robust secondary responsiveness. Here we show that CD8(+) T cells responding to different epitopes of influenza virus received qualitatively different signals during the primary response that altered their secondary responsiveness. Nucleoprotein (NP)-specific CD8(+) T cells encountered antigen on CD40-licensed, CD70-expressing, CD103(-)CD11b(hi) dendritic cells (DCs) at later times in the primary response. As a consequence, they maintained CD25 expression and responded to interleukin-2 (IL-2) and CD27, which together programmed their robust secondary proliferative capacity and interferon-gamma (IFN-gamma)-producing ability. In contrast, polymerase (PA)-specific CD8(+) T cells did not encounter antigen-bearing, CD40-activated DCs at later times in the primary response, did not receive CD27 and CD25 signals, and were not programmed to become memory CD8(+) T cells with strong proliferative and cytokine-producing ability. As a result, CD8(+) T cells responding to abundant antigens, like NP, dominated the secondary response.

    • Imai, Y., et al (2015). "Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate gammadelta-Low T Cells" J Immunol 195(2): 421-425.

      Programmed cell death 1 (PD-1) is a key regulatory molecule that has been targeted in human cancers, including melanoma. In clinical testing, Abs against PD-1 have resulted in psoriasiform dermatitis (PsD). To determine whether PD-1 regulates PsD, we compared skin responses of PD-1-deficient (PD-1KO) mice and wild-type (WT) controls in an imiquimod (IMQ)-induced murine model of psoriasis. PD-1KO mice showed severe epidermal hyperplasia, greater neutrophilic infiltration, and higher expression of Th17 cytokines (versus WT mice). IMQ exposure increased PD-1 expression by skin gammadelta-low (GDL) T cells and enhanced expression of PD-L1 by keratinocytes. Three-fold increases in the percentage of IL-17A(+) GDL T cells were observed in skin cell suspensions derived from IMQ-treated PD-1KO mice (versus WT controls), suggesting that the lack of PD-1 has a functional effect not only on alphabeta T cells, but also on GDL T cells, and that PD-1 may play a regulatory role in PsD.

    Product Citations

    • Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8+T cell infiltration mediated by Rela/NF-kB-Cxcl9 axis.

      In Front Immunol on 23 February 2026 by Liang, Y., Wu, Y., et al.

      PubMed

      Emotional distress (ED) is closely associated with the progression of triple-negative breast cancer (TNBC). Xiaoyao San (XYS), a classical Chinese herbal prescription traditionally used for mood regulation, has demonstrated potential therapeutic efficacy in emotion-related breast cancer. However, the molecular mechanisms through which XYS mitigates ED-induced TNBC (ED-TNBC) remain insufficiently characterized. This study aimed to investigate the therapeutic effects of XYS on ED-TNBC and elucidate its underlying molecular mechanisms.

    • WNT pathway inhibition sensitizes HAT1-high lung cancers to treatment with PD-1 inhibitors.

      In Cancer Cell Int on 24 October 2025 by Yang, T., Xie, Z., et al.

      PubMed

      Immunotherapies change the paradigm of current pulmonary oncological clinics, although majority of patients fail to benefit from these treatment modalities. HAT1 overexpression is frequently diagnosed in lung cancer patients. Effective immunotherapeutic scheme remains to be determined for this portion of patients.

    • Gene Therapy with Enterovirus 3 C Protease: A Promising Strategy for Various Solid Tumors.

      In Nat Commun on 8 May 2025 by Yang, X., Li, W., et al.

      PubMed

      Current cancer gene therapies rely primarily on antitumor immunity, but the exploration of alternative mRNA cargoes for direct antitumor effects is crucial to expand cancer gene therapies. Here we show that lipid nanoparticles (LNPs) carrying mRNA encoding a viral 3 C protease can efficiently suppress tumors by selectively inducing tumor cell apoptosis. In various solid tumor models, intracranial injection of LNPs carrying mRNA encoding the 3 C protease (3C-LNPs) significantly inhibits tumor growth and prolongs survival in glioblastoma models. Similarly, subcutaneous injection reduces tumor volume and inhibits angiogenesis in a breast cancer model, while intravenous injection inhibits tumor growth and angiogenesis and prolongs survival in hepatocellular carcinoma models. Mass spectrometry and cleavage site prediction assays identify heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) as the main target degraded by the 3 C protease. This study suggests that viral protease mRNA could be a promising broad-spectrum antitumor therapeutic.

    • Short-chain fatty acids are a key mediator of gut microbial regulation of T cell trafficking and differentiation after traumatic brain injury

      In Research Square on 21 November 2024 by Celorrio, M., Shumilov, K., et al.

    Product FAQs

    Related Products

    1. Catalog #BE0369
      InVivoMAb polyclonal llama IgG Read more
    2. Catalog #BP0290
      InVivoPlus rat IgG1 isotype control, anti-trinitrophenol Read more
    3. Catalog #BP0087
      InVivoPlus polyclonal Syrian hamster IgG Read more
    4. Catalog #BE0087
      InVivoMAb polyclonal Syrian hamster IgG Read more
    5. Catalog #BE0094
      InVivoMAb polyclonal rat IgG Read more
    6. Catalog #BE0095
      InVivoMAb polyclonal rabbit IgG Read more
    7. Catalog #BE0093
      InVivoMAb polyclonal mouse IgG Read more
    8. Catalog #BE0092
      InVivoMAb polyclonal human IgG Read more
    9. Catalog #BE0130
      InVivoMAb polyclonal goat IgG Read more
    10. Catalog #BE0290
      InVivoMAb rat IgG1 Isotype control, anti-trinitrophenol Read more

    Additional Formats